Episode
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
- Podcast
- Breast Cancer Update
- Published
- Nov 20, 2025
- Duration seconds
- 3516
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/breast-cancer-update-757579/episodes/hr-positive-metastatic-breast-cancer-an-interview-with-dr-erika-hamilton-on-the-potential-role-of-protac-estrogen-receptor-degraders/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/breast-cancer-update-757579/hr-positive-metastatic-breast-cancer-an-interview-with-dr-erika-hamilton-on-the-potential-role-of-protac-estrogen-receptor-degraders.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. CME information and select publications here .